[go: up one dir, main page]

DK3584317T5 - Clostridium histolyticum enzym - Google Patents

Clostridium histolyticum enzym Download PDF

Info

Publication number
DK3584317T5
DK3584317T5 DK19174182.6T DK19174182T DK3584317T5 DK 3584317 T5 DK3584317 T5 DK 3584317T5 DK 19174182 T DK19174182 T DK 19174182T DK 3584317 T5 DK3584317 T5 DK 3584317T5
Authority
DK
Denmark
Prior art keywords
clostridium histolyticum
enzyme
histolyticum enzyme
clostridium
histolyticum
Prior art date
Application number
DK19174182.6T
Other languages
English (en)
Other versions
DK3584317T3 (en
Inventor
Wayne Herber
Original Assignee
Endo Global Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Ventures filed Critical Endo Global Ventures
Application granted granted Critical
Publication of DK3584317T3 publication Critical patent/DK3584317T3/da
Publication of DK3584317T5 publication Critical patent/DK3584317T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24027—Thermolysin (3.4.24.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
DK19174182.6T 2012-01-12 2013-01-10 Clostridium histolyticum enzym DK3584317T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585909P 2012-01-12 2012-01-12
EP13736040.0A EP2802652B1 (en) 2012-01-12 2013-01-10 Clostridium histolyticum enzyme

Publications (2)

Publication Number Publication Date
DK3584317T3 DK3584317T3 (en) 2022-01-03
DK3584317T5 true DK3584317T5 (da) 2022-01-17

Family

ID=48782075

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19174182.6T DK3584317T5 (da) 2012-01-12 2013-01-10 Clostridium histolyticum enzym
DK13736040.0T DK2802652T3 (da) 2012-01-12 2013-01-10 Clostridium histolyticum enzym

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13736040.0T DK2802652T3 (da) 2012-01-12 2013-01-10 Clostridium histolyticum enzym

Country Status (13)

Country Link
US (7) US9757435B2 (da)
EP (4) EP2802652B1 (da)
JP (5) JP6263755B2 (da)
AU (6) AU2013208028B2 (da)
BR (1) BR112014017229B1 (da)
CA (2) CA2970639C (da)
DK (2) DK3584317T5 (da)
ES (3) ES2740499T3 (da)
HU (2) HUE057423T2 (da)
MX (1) MX351448B (da)
NZ (6) NZ750379A (da)
PT (2) PT2802652T (da)
WO (1) WO2013106510A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391899B1 (en) 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Delivery of therapeutic agents by a collagen binding protein
DK3584317T5 (da) * 2012-01-12 2022-01-17 Endo Global Ventures Clostridium histolyticum enzym
RU2540919C1 (ru) * 2013-09-27 2015-02-10 Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести
PT107276B (pt) * 2013-11-07 2018-06-07 Univ Aveiro Método para produção de colagenase recombinante para digestão de colagénios
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
WO2018104538A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
KR20230003601A (ko) 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase
CZ308157B6 (cs) 2017-09-13 2020-01-29 MB PHARMA s.r.o. Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
BR112021005064A2 (pt) 2018-09-18 2021-06-08 Endo Global Aesthetics Limited método para reduzir a gravidade da celulite em ambas as nádegas de um paciente humano
CN109355222B (zh) * 2018-11-06 2020-06-02 上海交通大学 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用
KR20210113271A (ko) 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
JP2022529565A (ja) * 2019-02-14 2022-06-23 ノルドマルク ファーマ ゲーエムベーハー コラゲナーゼタイプｉ、コラゲナーゼタイプｉｉ、中性プロテアーゼ、およびクロストリパインからなる群から選択される少なくとも１種の酵素のクロマトグラフィー精製
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
EP4448752A1 (en) * 2021-12-14 2024-10-23 Ramot at Tel-Aviv University Ltd. Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821364A (en) * 1966-07-08 1974-06-28 Advance Biofactures Corp Process of producing collagenase
JPS5662229A (en) 1979-10-25 1981-05-28 Asahi Glass Co Ltd Electro-optical dimming panel
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
CA1227132A (fr) 1983-01-05 1987-09-22 Robert J. Weill Preparation a activite collagenolytique ayant une activite elevee et compositions pharmaceutiques la contenant
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4542065A (en) 1984-05-21 1985-09-17 Ppg Industries, Inc. Chemically treated glass fibers and strands and dispersed products thereof
JPS61289885A (ja) 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
US5252461A (en) 1990-05-01 1993-10-12 The Regents Of The Univ. Of California Mixed immunoglobulins for detection of rheumatoid factors
CA2047306A1 (en) 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5256140A (en) 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
JPH08500970A (ja) * 1992-06-22 1996-02-06 トライジェン，インコーポレーテッド ヒストリチクス菌からのコラゲナーゼ産生に応答性の遺伝子の分子クローニング
CA2152898C (en) 1992-12-30 2003-04-29 Hans Israelsen Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
JP3186881B2 (ja) 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
CA2189646C (en) 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6146626A (en) 1995-03-16 2000-11-14 Knoll Aktiengesellschaft Defined enzyme mixtures for obtaining cells and treating wounds
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
DK0925364T3 (da) 1996-09-06 2003-02-24 Bioteknologisk Inst Et regulerbart ekspressionssystem til brug i mælkesyrebakterier
BR9713108A (pt) * 1996-11-19 2004-06-22 Roche Diagnostics Gmbh Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US5753785A (en) 1996-12-16 1998-05-19 Fina Technology, Inc. Production of E-B copolymers with a single metallocene catalyst and a single monomer
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
EP1024788A1 (en) 1997-10-03 2000-08-09 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
GB9724802D0 (en) 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
US20020036328A1 (en) 1998-11-16 2002-03-28 William R. Richards, Jr. Offset drain fermi-threshold field effect transistors
FR2788682B1 (fr) 1999-01-26 2001-04-06 Seb Sa Dispositif de thermographie
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
RU2180002C2 (ru) 1999-08-16 2002-02-27 Пермское научно-производственное объединение "Биомед" Способ получения коллагеназы
EP1207840B1 (en) 1999-08-20 2004-10-13 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
US6280993B1 (en) * 1999-08-24 2001-08-28 Ichiro Yamato Gene encoding class I collagenase
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
ES2284528T3 (es) 1999-09-24 2007-11-16 Proteon Therapeutics, Inc. Utilizacion de elastasa para abrir arterias y venas obstruidas.
US7811250B1 (en) 2000-02-04 2010-10-12 Boston Scientific Scimed, Inc. Fluid injectable single operator exchange catheters and methods of use
EP1187602A4 (en) 2000-04-18 2004-09-15 Peptron Inc SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME
NZ525394A (en) 2000-10-20 2005-12-23 Bioneer As Improved fermentation method for production of heterologous gene products in lactic acid bacteria
EP1355566B1 (en) 2000-12-18 2012-11-28 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
WO2002060410A2 (en) 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
JP4266817B2 (ja) 2001-07-02 2009-05-20 ノルドマルク・アルツナイミッテル・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト 酵素の精製方法およびその方法で製造された精製済み酵素並びに該酵素の用途
GB0124124D0 (en) 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
JP2003284553A (ja) 2002-03-28 2003-10-07 Seikagaku Kogyo Co Ltd 生理活性タンパク質
CN1662177A (zh) 2002-06-25 2005-08-31 超形态公司 用于形体美学的设备和方法
EP1433845A1 (en) * 2002-12-23 2004-06-30 Georg-August-Universität Clostridium tetani collagenase and uses thereof
EP1462519A1 (en) 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
EP1709194A4 (en) 2003-12-17 2007-07-25 Univ Columbia DISTRIBUTION OF DNA OR RNA VIA NEXI OF HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SIRNA
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
TR201802446T4 (tr) 2004-05-19 2018-03-21 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Sodyum deoksikolat içeren enjeksiyonluk bileşim.
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
AU2005259689B2 (en) 2004-07-07 2011-10-06 H. Lundbeck A/S Novel carbamylated EPO and method for its production
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20060020448A1 (en) 2004-07-21 2006-01-26 Microsoft Corporation Method and apparatus for capitalizing text using maximum entropy
EP1785410A4 (en) 2004-08-30 2010-04-21 Daicel Chem Polyglycerol monoethers and process for producing the same
JP4923131B2 (ja) 2004-08-30 2012-04-25 株式会社リコー ログ収集システム、ログ収集装置およびログ収集プログラム
US20150025420A1 (en) 2004-10-06 2015-01-22 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
DE102004060075A1 (de) 2004-12-14 2006-07-06 Merck Patent Gmbh Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
SI1846022T1 (sl) 2005-01-21 2016-01-29 The Research Foundation Of State University Of New York Postopki za zdravljenje adhezivnega kapsulitisa
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
JP2006254876A (ja) 2005-03-18 2006-09-28 Hokkaido Univ Ｌ−トリプトファン製造法
US20060241673A1 (en) 2005-04-21 2006-10-26 Zadini Filiberto P Subcision device
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US20070031482A1 (en) 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
WO2007112996A2 (en) 2006-03-31 2007-10-11 Dsm Ip Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
WO2008100833A2 (en) 2007-02-13 2008-08-21 Auxilium International Holdings, Inc. Production of recombinant collagenases colg and colh in escherichia coli
CN101678088B (zh) 2007-02-14 2014-01-08 友莱尔皮肤产品有限责任公司 修饰的突变体胶原蛋白酶及其在脂肪溶解和疤痕减少中的应用
JP2009532509A (ja) 2007-05-11 2009-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 美容活性成分の送達に有用なゲル
US9987221B2 (en) 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
KR101633612B1 (ko) 2007-10-26 2016-06-27 코닌클리케 필립스 엔.브이. 광각 선택 광 검출기 장치
EP2217614A4 (en) 2007-11-07 2011-12-07 Dynamic Microbials Ltd ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND APPLICATIONS THEREOF
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
ES2388219T3 (es) 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
AU2009274229B2 (en) 2008-07-21 2013-08-22 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8380531B2 (en) 2008-07-25 2013-02-19 Invivodata, Inc. Clinical trial endpoint development process
CA2741334A1 (en) 2008-10-22 2010-04-29 Allergan, Inc. Clinical assessment scales and methods
EP2344153A1 (en) 2008-11-11 2011-07-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Compound useful for treating cellulite
KR101700974B1 (ko) * 2008-11-19 2017-01-31 고쿠리츠다이가쿠호진 도호쿠다이가쿠 친화성 태그가 결합된 융합 콜라게나제 및 그의 제조방법
IT1397646B1 (it) * 2009-12-15 2013-01-18 Seidita Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione.
US9132199B2 (en) 2010-03-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and uses therefor
US20130195828A1 (en) 2010-04-14 2013-08-01 Northwestern University Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques
US20130217789A1 (en) 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US10119131B2 (en) 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
TWI461214B (zh) 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
WO2013059263A1 (en) 2011-10-17 2013-04-25 Sound Surgical Technologies, Llc Ultrasonic probe for treating cellulite
PL3581199T3 (pl) 2011-10-21 2023-09-11 Endo Global Ventures Sposoby leczenia lub zmniejszania panikulopatii obrzękowo- zwłóknieniowo-stwardnieniowej
DK3584317T5 (da) * 2012-01-12 2022-01-17 Endo Global Ventures Clostridium histolyticum enzym
US9933436B2 (en) 2012-09-07 2018-04-03 Shiseido Company, Ltd. Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
US10369110B2 (en) 2013-03-15 2019-08-06 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN105050580B (zh) 2013-03-15 2017-11-28 玫琳凯有限公司 化妆品组合物及其用途
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
EP3145515B1 (en) 2014-06-27 2023-07-05 Medytox Inc. Formulations comprising cholate and/or chenodeoxycholate for non-surgical removal of a localized fat deposit
CA3013776A1 (en) 2016-02-08 2017-08-17 OutcomeMD, Inc. Determining a wellness, improvement, or effectiveness score
ES2886651T3 (es) 2016-10-28 2021-12-20 Merz Pharma Gmbh & Co Kgaa Tratamiento cosmético de la celulitis
KR20230003601A (ko) 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase

Also Published As

Publication number Publication date
AU2016208378B2 (en) 2018-10-11
AU2013208028A1 (en) 2014-08-07
US20180055918A1 (en) 2018-03-01
HUE046160T2 (hu) 2020-02-28
EP3584317B1 (en) 2021-11-24
JP7354197B2 (ja) 2023-10-02
BR112014017229B1 (pt) 2022-05-17
EP2802652A4 (en) 2015-10-14
MX351448B (es) 2017-10-16
US9757435B2 (en) 2017-09-12
EP2802652B1 (en) 2019-06-05
EP2802652A2 (en) 2014-11-19
JP2019103505A (ja) 2019-06-27
JP2018075011A (ja) 2018-05-17
EP3584317A1 (en) 2019-12-25
AU2021221653B2 (en) 2023-10-05
PT3584317T (pt) 2022-01-26
ES2740499T3 (es) 2020-02-05
US20150010532A1 (en) 2015-01-08
EP4276180A2 (en) 2023-11-15
AU2016208384B2 (en) 2018-09-13
EP4276180A3 (en) 2024-01-10
US20240269245A1 (en) 2024-08-15
JP6947888B2 (ja) 2021-10-13
US11975054B2 (en) 2024-05-07
AU2023229488A1 (en) 2023-09-28
NZ797997A (en) 2024-05-31
PT2802652T (pt) 2019-09-10
AU2019200192A1 (en) 2019-04-04
EP4015627B1 (en) 2023-09-27
NZ750379A (en) 2022-10-28
NZ627372A (en) 2016-04-29
AU2019200192B2 (en) 2021-07-01
AU2021221653A1 (en) 2021-09-23
JP6496386B2 (ja) 2019-04-03
MX2014008441A (es) 2015-03-13
JP2022023041A (ja) 2022-02-07
NZ733709A (en) 2022-10-28
CA2861033C (en) 2017-07-25
AU2013208028B2 (en) 2016-04-28
NZ766918A (en) 2023-03-31
JP2015506176A (ja) 2015-03-02
US20240252602A1 (en) 2024-08-01
US20250041391A1 (en) 2025-02-06
CA2970639A1 (en) 2013-07-18
US10603365B2 (en) 2020-03-31
AU2016208384C1 (en) 2023-10-05
WO2013106510A2 (en) 2013-07-18
AU2016208378A1 (en) 2016-08-18
ES2968836T3 (es) 2024-05-14
WO2013106510A3 (en) 2013-10-03
AU2016208384A1 (en) 2016-08-11
BR112014017229A8 (pt) 2021-06-08
CA2861033A1 (en) 2013-07-18
US11879141B2 (en) 2024-01-23
BR112014017229A2 (pt) 2017-06-13
JP6752309B2 (ja) 2020-09-09
ES2904884T3 (es) 2022-04-06
US20230416717A1 (en) 2023-12-28
JP2020188810A (ja) 2020-11-26
NZ718173A (en) 2017-09-29
DK3584317T3 (en) 2022-01-03
HUE057423T2 (hu) 2022-05-28
JP6263755B2 (ja) 2018-01-24
US20200206326A1 (en) 2020-07-02
EP4015627A1 (en) 2022-06-22
CA2970639C (en) 2022-04-26
DK2802652T3 (da) 2019-07-15

Similar Documents

Publication Publication Date Title
DK3584317T5 (da) Clostridium histolyticum enzym
DK3354728T3 (da) Alpha-amylase-varianter
EP2880158A4 (en) Enzymes
DK3372239T3 (da) Manipuleret botulinumneurotoksin
DK3027742T3 (da) Enzymvarianter
DK3967757T3 (da) Alfa-amylasevarianter afledt fra alfa-amylasen fra cytophaga sp. amylase (cspamy2)
DK2893011T3 (da) Vaske- eller rengøringsmiddel med forbedret enzym-ydeevne
BR112014024373A2 (pt) anticorpos regulados por protease
DK3326644T3 (da) Rekombinante clostridium botulinum-neurotoksiner
BR112014004780A2 (pt) novas enzimas celobio-hidrolase
BR112015000507A2 (pt) inibição de enzimas
EP2866024A4 (en) ENZYMATIC ELECTRODE
DK3205351T3 (da) Enzym til lysosomale lagringssygdomme
HK1207880A1 (en) Improved enzyme variants
CL2014002030A1 (es) Alfa-amilasa
EP2866025C0 (en) Enzyme electrode
FR2988733B1 (fr) Microorganisme recombinant
GB201207018D0 (en) Enzymes
FR2987162B1 (fr) Contact mobile bistable
EP2970932A4 (en) ENZYMES WITH PULLULANASE ACTIVITY
GB201223308D0 (en) Enzyme inhibitors
GB201211978D0 (en) Enzyme
FR3000147B1 (fr) Rondelle autobloquante
FI20105700A0 (fi) Entsyymielektrodi
FI20125307L (fi) Bioreaktori